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INTRODUCTION
Spontaneous regression of malignant melanoma
is defined by the disappearance of melanocytic
neoplastic cells partially or completely. In contrast
to the partial form, complete spontaneous regression
of primary malignant melanoma is a rare-occurring
phenomenon, with 76 cases reported in the literature
since 1866.1 The criteria for the diagnosis of regres-
sion were established by Smith and Stehlin2 and
modified later.3,4 Overall, the impact of partial or
complete regression on prognosis is anecdotal and
controversial; however, we report a case with com-
plete regression of a histologically diagnosed thick
primary malignant melanoma with rapid develop-
ment of metastatic disease and death.
CASE REPORT
A 49-year-old man was referred to the surgical
oncology department after biopsy of a lesion on the
left chest found a newly diagnosed melanoma. The
skin lesion was present for several years and had
recently grown larger and darker without associated
pain or pruritus. Pathologic examination found a
nodular melanoma, broadly transected along the
base, at least 8 mm in depth, level IV with extensive
ulceration. There were 12 mitoses per square milli-
meter with positive immunohistochemical staining
for Mart-1 and HMB-45 and an increased Ki-67
proliferation index of greater than 25% (Fig 1).
Tumor-infiltrating lymphocytes were nonbrisk, and
there was no evidence of tumor regression.
The patient did not have a family history of
melanoma and did not exhibit signs of a new cough,
melena, hematochezia, or headache at the time of
initial presentation. His physical examination was
notable for a palpable, mobile 1- to 2-cm lymph
node in the left supraclavicular fossa and a 1- 3
0.5-cm, intact, elliptical pigmented primary mela-
noma on his anterior chest. Thus, the patient was
scheduled for staging scans, ultrasound scan with
fine-needle aspiration of his left supraclavicular
lymph node, and wide local excision of the
melanoma on his chest. Computed tomography
scans of the chest, abdomen, and pelvis along with
magnetic resonance imaging (MRI) of the brain did
not show evidence of metastatic disease; however,
Fig 1. Left side of the chest skin biopsy for primary
malignant melanoma. Histopathologic examination found
a thick primary melanoma characterized by atypical
pigmented epithelioid cells with extensive ulceration.
(Hematoxylin-eosin stain; original magnification: 3100.)
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results of fine-needle aspiration of the palpable
lymphadenopathy on the left side of the neck were
positive for melanoma, placing the disease at stage
III. At follow-up 4 weeks later, the patient had no
residual pigmentation at the site of his original
melanoma (Fig 2), a distinct clinical change since
his initial presentation.
He then underwent wide local excision of the left
anterior chest melanoma site with left cervical
lymphadenectomy. Interestingly, pathology findings
from the left anterior chest skin excision showed
multifocal satellite melanoma metastases present in
the dermis and subcutaneous fat with absence of the
primary lesion (Fig 3). Snapshot polymerase chain
reaction assay performed on the specimen was
positive for variants in BRAF and STK11. In addition,
the patient had 2 lymph nodes that were positive for
melanoma with the largest macrometastasis entirely
replacing the lymph node with extracapsular exten-
sion, placing the disease at stage IIIC (T4bN3M0).
The patient was subsequently offered adjuvant
interferon therapy, but he deferred treatment and
was placed on active surveillance with a planned
return date of 3 months.
Three months later, as part of routine surveillance,
the patient had an lactate dehydrogenase level
of 1591 IU/L with multiple new foci of intra-
abdominal disease; in addition, he had increasing
pulmonary nodules and bilateral hilar, peribronchial,
periesophageal, and left axillary lymphadenopathy
suspicious for metastasis. HeadMRI found numerous
enhancing lesions scattered throughout both cere-
bral hemispheres, and computed tomography of the
neck showed an enhancing nodule suspicious for
tumor recurrence (Fig 4).
The patient was started on vemurafenib and
cobimetinib; after 3 months of therapy with
continued brain metastases, the patient underwent
whole-brain radiotherapy followed by treatment
with ipilimumab, nivolumab, and dabrafenib.
Unfortunately, the patient died 1 month later of
cerebral edema.
DISCUSSION
We present a patient who had rapid development
of metastatic disease from a thick, at least 8-mm
primary lesion detected with clinically positive
lymph node disease. Between the patient’s first and
second preoperative visits, his primary lesion
completely regressed, and aggressive dermal disease
was found at resection. This finding is of clinical
interest given the occasional presentation of mela-
noma with unknown primary tumor thought to be
caused by spontaneous complete regression. In
addition, this case shows the rapid changes in tumor
presentation, behavior, and metastatic potential
associated with this process.
Available literature on the complete regression of
primary malignant melanoma shows that it is a rare
phenomenon, with an incidence of 0.22% to 0.27%.5
The significance of primary regression on the
prognosis of melanoma patients is controversial;
however, the incidence of metastatic disease in the
setting of complete regression of the primary lesion
is estimated to range from 4% to 10%.3 These
data have led clinicians to believe that complete
regression of primary malignant melanoma may
Fig 2. Clinical photograph of the primary melanoma on
the left side of the chest 4 weeks after biopsy. The clinically
notable pigmented lesion had regressed to a small scaled
area of skin.
Fig 3. Histologic evaluation of the site of the primary
lesion showed a scar with no residual melanoma identi-
fied. (Hematoxylin-eosin stain; original magnification:
340.)
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have an association with progressive metastatic
disease. However, one must keep in mind that the
regression of a primary melanoma usually comes
to attention when associated with metastasis,
leading to underreporting of nonmetastatic cases.4,6
Interestingly, metastatic disease was also signifi-
cantly increased among cases of thin melanoma
with extensive ([50%) regression, suggesting that
these lesions are either understaged or exhibit
unfavorable biology associated with spontaneous
regression.6
Although the mechanism of spontaneous regres-
sion is not fully understood, immunologic factors are
considered a key aspect of this process. One poten-
tial explanation for spontaneous regression is via a
natural tumor-specific cytolytic T-cell response not
seen in subsequent melanoma metastases.7 Another
theory posits that complete regression of a primary
malignant melanoma is caused by the immune-
stimulating presence of metastatic melanoma within
a regional lymph node.8 Lastly, others propose that
operative trauma or infection can act as mediating
factors that may increase an individual’s immune
response against a tumor.9 These theories all suggest
that innate immune cells may recognize distinct
structures on cancer cells, triggering complete
regression of the primarymalignancy. The continued
presence of metastatic lesions, however, may indi-
cate immune escape through such possible mecha-
nisms as mutation or down-regulation of human
leukocyte antigen, myeloid-derived suppressor cells,
or the production of suppressive cytokines.
Although the mechanism and prognosis of spon-
taneous regression of primary malignant melanoma
is uncertain, it is interesting to note the aggressive
and rapid progression from a cutaneous primary
melanoma to widely metastatic disease in a few short
months. Our case suggests that a completely regress-
ing, thick primary melanoma in the setting of
metastatic disease may portend a poor prognosis,
showing a need for vigilant clinical and radiologic
observation.
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Fig 4. MRI T1 postcontrast axial image shows more than
100 new enhancing hemorrhagic intracranial metastases
throughout the cerebral hemispheres.
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